This activity is jointly provided by Center for Independent Healthcare Education and PharmaCom Group, Inc. Supported by an educational grant from BioDelivery Sciences International, Inc.
This activity is not certified for credit.
Date
Friday, September 10
Start Time
12:30p
End Time
1:30p
Room
Castellana
Level 3
Program Description
Opioids remain an important part of our analgesic armamentarium, but can also have serious adverse consequences. As a result, the benefit-risk balance of opioid analgesics has come under renewed scrutiny. However, all opioids are not the same and they vary in their potential for respiratory depression, the major cause of overdose death. Unlike conventional opio ids that primarily rely on mu-opioid receptor agonism for analgesia (and adverse effects), atypical opioids have additional mechanisms of action that increase the separation between desired therapeutic benefits and unwanted risks. In particular, buprenorphine has been identified as a preferred opioid for chronic pain because it has a ceiling to respiratory depression. However, buprenorphine’s complex pharmacology and development history, which includes its use to treat opioid use disorder, have led to longstanding misconceptions that it is a weaker, older drug with limited utility for pain management. The faculty will describe the pharmacology, analgesic efficacy, and safety of buprenorphine, and illustrate the appropriate use of buprenorphine for chronic pain, including conversion strategies for switching from conventional opioids to buprenorphine.
Faculty
Jeff Gudin, MD
Lynn R. Webster, MD
Pre-event Registration
https://www.surveymonkey.com/r/BDSI2021PW
Lunch will be served
Contact Name
Stephanie Lee
Contact Phone
(978) 886-0064
Contact email
[email protected]